Cao received the Distinguished Employee Award, Innovation Award etc. She evaluated, negotiated and executed 36 technology collaboration deals to expedite the company’s drug discovery and development process. Cao joined business development team focusing on technology transactions. At BMS, she was responsible for global business development at CMO (contract manufacture operation) and accomplished significant sales growth. Cao increased the business revenue 600% in 4 years. Manager of Business Development, Associate Director of Global Manufacturing and Supply Chain, and Sr. She previously worked at Tyger Scientific, Ferro, Bristol-Myer Squibb (BMS) and Abzena, and held positions of Director of Sales and Marketing, Sr. Cao graduated from Tianjin University with a BS in Material Science & Engineering and MS in Chemical Engineering and obtained her MS in Organic Chemistry at Michigan State University. Ping Cao, Senior Vice President and Chief Business Development Officer, is in charge of the Business Development Department, responsible for the Company's business cooperation with external partners, including licensing in and out, authorization, partnership alliance, merger and acquisition. In addition, he is the member of the Pharmaceutical Innovation Investment Specialty Committee of China Pharmaceutical Innovation and Research Development Association (PhIRDA), the vice-chairman of Shanghai Biopharmaceutics Industry Association (SBIA) and the member of the 9th council of Shanghai Pharmaceutical Profession Association (SPPA). Under his leadership, Henlius was awarded 2021 National Worker Pioneer, 2021 Shanghai Worker Pioneer, 2020 Shanghai Model Group and 2019 Shanghai Worker Pioneer. He was awarded Shanghai Labor Medal, Outstanding Technology Development Talent of Hangzhou, Second Prize for Science and Technology Progress Award of Zhejiang Province and First Prize for Science and Technology Progress Award of Hangzhou. He has been involved in the development of a Category II new drug, the first listed recombinant human granulocyte colony-stimulating factor (rhG-CSF) injection in China. James is experienced in biopharmaceutical development and production, and familiar with all types of national laws and regulations. and Shanghai Chemo Wanbang Biopharma Co., Ltd. He has previously served as research manager and chief engineer in Hangzhou Jiuyuan Gene Engineering Co., Ltd., Hangzhou Taishi Biotechnology Co., Ltd. James Guo, Senior Vice President, graduated from Genetics and Genetic Engineering Department of Fudan University, and holds a MBA degree from Zhejiang University.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |